Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Methods to promote equity in health resource allocation in low- and middle-income countries: an overview.

Love-Koh J, Griffin S, Kataika E, Revill P, Sibandze S, Walker S.

Global Health. 2020 Jan 13;16(1):6. doi: 10.1186/s12992-019-0537-z. Review.

2.

Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance.

Phillips A, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, Rehle T, Tanser F, Moyo S, Shahmanesh M, Castor D, Russell E, Jamieson L, Bansi-Matharu L, Shroufi A, Barnabas R, Parikh UM, Mellors JW, Revill P.

J Infect Dis. 2019 Dec 18. pii: jiz667. doi: 10.1093/infdis/jiz667. [Epub ahead of print]

3.

A PCR assay to quantify patterns of HBV transcription.

D'Arienzo V, Magri A, Harris JM, Wing PAC, Ko C, Rubio CO, Revill PA, Protzer U, Balfe P, McKeating JA.

J Gen Virol. 2019 Dec 17. doi: 10.1099/jgv.0.001373. [Epub ahead of print]

PMID:
31846416
4.

Analysis of the in vitro replication phenotype of African hepatitis B virus (HBV) genotypes and subgenotypes present in Australia identifies marked differences in DNA and protein expression.

Bannister E, Sozzi V, Mason H, Locarnini S, Hardikar W, Revill PA.

Virology. 2020 Jan 15;540:97-103. doi: 10.1016/j.virol.2019.11.001. Epub 2019 Nov 7.

PMID:
31765921
5.

Examining the use of economic evaluations in health-related humanitarian programmes in low- and middle-income countries: a systematic review.

Makhani LA, Moran V, Sadique Z, Singh NS, Revill P, Roberts B.

Health Policy Plan. 2019 Nov 7. pii: czz144. doi: 10.1093/heapol/czz144. [Epub ahead of print]

PMID:
31697373
6.

Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Wilson D, Jani I, Apollo T, Sculpher M, Hallett T, Kerr C, van Oosterhout JJ, Eaton JW, Estill J, Williams B, Doi N, Cowan F, Keiser O, Ford D, Hatzold K, Barnabas R, Ayles H, Meyer-Rath G, Nelson L, Johnson C, Baggaley R, Fakoya A, Jahn A, Revill P.

J Int AIDS Soc. 2019 Jul;22(7):e25325. doi: 10.1002/jia2.25325.

7.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

8.

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.

Revill PA, Penicaud C, Brechot C, Zoulim F.

Genes (Basel). 2019 Apr 1;10(4). pii: E260. doi: 10.3390/genes10040260. Review.

9.

A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities.

Arnold M, Griffin S, Ochalek J, Revill P, Walker S.

Cost Eff Resour Alloc. 2019 Mar 20;17:7. doi: 10.1186/s12962-019-0175-6. eCollection 2019.

10.

The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis.

Cambiano V, Johnson CC, Hatzold K, Terris-Prestholt F, Maheswaran H, Thirumurthy H, Figueroa C, Cowan FM, Sibanda EL, Ncube G, Revill P, Baggaley RC, Corbett EL, Phillips A; for Working Group on Cost Effectiveness of HIV self-testing in Southern Africa.

J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25243. doi: 10.1002/jia2.25243.

11.

Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.

Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett TB, Phillips AN, Bekker LG, Rees H, Gray G.

Vaccine. 2019 Apr 10;37(16):2258-2267. doi: 10.1016/j.vaccine.2019.02.073. Epub 2019 Mar 16.

12.

The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.

Bórquez A, Guanira JV, Revill P, Caballero P, Silva-Santisteban A, Kelly S, Salazar X, Bracamonte P, Minaya P, Hallett TB, Cáceres CF.

Lancet Public Health. 2019 Mar;4(3):e127-e136. doi: 10.1016/S2468-2667(18)30236-6. Epub 2019 Jan 23.

13.

Appraising the value of evidence generation activities: an HIV modelling study.

Woods B, Rothery C, Anderson SJ, Eaton JW, Revill P, Hallett TB, Claxton K.

BMJ Glob Health. 2018 Dec 7;3(6):e000488. doi: 10.1136/bmjgh-2017-000488. eCollection 2018.

14.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

15.

Fresh Money for Health? The (False?) Promise of "Innovative Financing" for Health in Malawi.

Chansa C, Mwase T, Matsebula TC, Kandoole P, Revill P, Makumba JB, Lindelow M.

Health Syst Reform. 2018;4(4):324-335. doi: 10.1080/23288604.2018.1506643. Epub 2018 Oct 29.

PMID:
30373454
16.

Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL.

Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005. Review. Erratum in: Value Health. 2019 Mar;22(3):383. Value Health. 2019 Apr;22(4):502.

PMID:
30314613
17.

Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.

McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC.

Gastroenterology. 2019 Jan;156(2):384-399. doi: 10.1053/j.gastro.2018.07.058. Epub 2018 Sep 27. Review.

18.

Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study.

Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA.

Lancet Glob Health. 2018 Dec;6(12):e1329-e1338. doi: 10.1016/S2214-109X(18)30401-7. Epub 2018 Sep 25.

19.

Cost-Effectiveness of Interventions to Prevent HIV Acquisition.

Garnett GP, Krishnaratne S, Harris KL, Hallett TB, Santos M, Enstone JE, Hensen B, Dallabetta G, Revill P, Gregson SAJ, Hargreaves JR.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 7.

20.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

Bannister EG, Yuen L, Littlejohn M, Edwards R, Sozzi V, Colledge D, Li X, Locarnini S, Hardikar W, Revill PA.

J Gen Virol. 2018 Aug;99(8):1103-1114. doi: 10.1099/jgv.0.001086. Epub 2018 Jun 22.

PMID:
29932395
21.

In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease.

Sozzi V, Shen F, Chen J, Colledge D, Jackson K, Locarnini S, Yuan Z, Revill PA.

Virology. 2018 Jun;519:190-196. doi: 10.1016/j.virol.2018.04.015. Epub 2018 May 4.

22.

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K.

BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018.

23.

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A.

Liver Int. 2018 Oct;38(10):1760-1769. doi: 10.1111/liv.13716. Epub 2018 Mar 6.

PMID:
29427368
24.

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.

Tierrablanca LE, Ochalek J, Ford D, Babiker A, Gibb D, Butler K, Turkova A, Griffin S, Revill P; BREATHER (PENTA 16) Trial Group.

Medicine (Baltimore). 2018 Feb;97(5):e9698. doi: 10.1097/MD.0000000000009698. Erratum in: Medicine (Baltimore). 2018 Feb;97(7):e0012.

25.

Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda.

Abongomera G, Chiwaula L, Revill P, Mabugu T, Tumwesige E, Nkhata M, Cataldo F, van Oosterhout J, Colebunders R, Chan AK, Kityo C, Gilks C, Hakim J, Seeley J, Gibb DM, Ford D.

Int Health. 2018 Jan 1;10(1):8-19. doi: 10.1093/inthealth/ihx061.

26.

Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.

Revill P, Walker S, Cambiano V, Phillips A, Sculpher MJ.

PLoS One. 2018 Jan 2;13(1):e0190283. doi: 10.1371/journal.pone.0190283. eCollection 2018.

27.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

28.

Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.

Barnabas RV, Revill P, Tan N, Phillips A.

J Int AIDS Soc. 2017 Nov;20 Suppl 7. doi: 10.1002/jia2.25006. Review.

29.

Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.

Shen F, Li Y, Wang Y, Sozzi V, Revill PA, Liu J, Gao L, Yang G, Lu M, Sutter K, Dittmer U, Chen J, Yuan Z.

Hepatology. 2018 Apr;67(4):1237-1252. doi: 10.1002/hep.29609. Epub 2018 Feb 22.

PMID:
29059468
30.

Pre-exposure prophylaxis is cost-effective for HIV in the UK.

Revill P, Dwyer E.

Lancet Infect Dis. 2018 Jan;18(1):10-11. doi: 10.1016/S1473-3099(17)30594-7. Epub 2017 Oct 17. No abstract available.

31.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

32.

Causal effects of HIV on employment status in low-income settings.

Ochalek J, Revill P, van den Berg B.

Econ Hum Biol. 2017 Nov;27(Pt A):248-260. doi: 10.1016/j.ehb.2017.09.001. Epub 2017 Sep 8.

33.

Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance.

Schulz TR, Edwards R, Thurnheer MC, Yuen L, Littlejohn M, Revill P, Chu M, Tanyeri F, Wade A, Biggs BA, Sasadeusz J.

J Med Virol. 2018 Feb;90(2):271-276. doi: 10.1002/jmv.24939. Epub 2017 Sep 26.

PMID:
28885711
34.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2018 Mar;67(3):1127-1131. doi: 10.1002/hep.29509. Epub 2018 Jan 24. No abstract available.

35.

Taxonomy of the order Mononegavirales: update 2017.

Amarasinghe GK, Bào Y, Basler CF, Bavari S, Beer M, Bejerman N, Blasdell KR, Bochnowski A, Briese T, Bukreyev A, Calisher CH, Chandran K, Collins PL, Dietzgen RG, Dolnik O, Dürrwald R, Dye JM, Easton AJ, Ebihara H, Fang Q, Formenty P, Fouchier RAM, Ghedin E, Harding RM, Hewson R, Higgins CM, Hong J, Horie M, James AP, Jiāng D, Kobinger GP, Kondo H, Kurath G, Lamb RA, Lee B, Leroy EM, Li M, Maisner A, Mühlberger E, Netesov SV, Nowotny N, Patterson JL, Payne SL, Paweska JT, Pearson MN, Randall RE, Revill PA, Rima BK, Rota P, Rubbenstroth D, Schwemmle M, Smither SJ, Song Q, Stone DM, Takada A, Terregino C, Tesh RB, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Volchkov VE, Wahl-Jensen V, Walker PJ, Wang B, Wang D, Wang F, Wang LF, Werren JH, Whitfield AE, Yan Z, Ye G, Kuhn JH.

Arch Virol. 2017 Aug;162(8):2493-2504. doi: 10.1007/s00705-017-3311-7. Epub 2017 Apr 7.

36.

Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team.

Int Health. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.

37.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S.

J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089. Erratum in: J Infect Dis. 2017 Nov 15;216(8):1048.

38.

The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.

Valaydon Z, Pellegrini M, Thompson A, Desmond P, Revill P, Ebert G.

Clin Transl Immunology. 2016 Dec 9;5(12):e115. doi: 10.1038/cti.2016.68. eCollection 2016 Dec. Review.

39.

Factors influencing job preferences of health workers providing obstetric care: results from discrete choice experiments in Malawi, Mozambique and Tanzania.

McAuliffe E, Galligan M, Revill P, Kamwendo F, Sidat M, Masanja H, de Pinho H, Araujo E.

Global Health. 2016 Dec 20;12(1):86. doi: 10.1186/s12992-016-0222-4.

40.

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Woods B, Revill P, Sculpher M, Claxton K.

Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.

41.

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG.

Value Health. 2016 Dec;19(8):921-928. doi: 10.1016/j.jval.2016.04.015.

42.

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, Ford D, Mugurungi O, Apollo T, Murungu J, Bangsberg DR, Revill P.

PLoS One. 2016 Dec 15;11(12):e0167654. doi: 10.1371/journal.pone.0167654. eCollection 2016.

43.

Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.

Thompson A, Locarnini S, Revill P.

Gut. 2017 Aug;66(8):1534-1535. doi: 10.1136/gutjnl-2016-313287. Epub 2016 Nov 24. No abstract available.

PMID:
27884921
44.

Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi.

Chiwaula LS, Revill P, Ford D, Nkhata M, Mabugu T, Hakim J, Kityo C, Chan AK, Cataldo F, Gibb D, van den Berg B; Lablite Project Team.

Value Health Reg Issues. 2016 Sep;10:73-78. doi: 10.1016/j.vhri.2016.08.002. Epub 2016 Sep 16.

45.

Genotypic profiles of hepatitis B in African immigrants and their clinical relevance.

Thurnheer MC, Edwards R, Schulz TR, Yuen L, Littlejohn M, Revill P, Bannister E, Chu M, Tanyeri F, Wade A, Biggs BA, Sasadeusz J.

J Med Virol. 2017 Jun;89(6):1000-1007. doi: 10.1002/jmv.24732. Epub 2016 Dec 9.

PMID:
27862013
46.

Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study.

Nkhata MJ, Muzambi M, Ford D, Chan AK, Abongomera G, Namata H, Mambule I, South A, Revill P, Grundy C, Mabugu T, Chiwaula L, Hakim J, Kityo C, Reid A, Katabira E, Sodhi S, Gilks CF, Gibb DM, Seeley J, Cataldo F; Lablite team.

BMC Health Serv Res. 2016 Nov 16;16(1):660.

47.

Ethics and hepatitis B cure research.

Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HL, Lim SG, Lewin SR.

Gut. 2017 Mar;66(3):389-392. doi: 10.1136/gutjnl-2016-313009. Epub 2016 Nov 14. No abstract available.

PMID:
27849559
48.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes.

Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, Yuen L, Locarnini SA, Revill PA.

J Virol. 2016 Oct 28;90(22):10054-10064. doi: 10.1128/JVI.01293-16. Print 2016 Nov 15.

49.

Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).

Revill P, Locarnini S.

Curr Opin Pharmacol. 2016 Oct;30:144-150. doi: 10.1016/j.coph.2016.08.015. Review.

PMID:
27639371
50.

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile.

Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, Rousseau C, Garnett G, Ehrenkranz P, Bansi-Matharu L, Vojnov L, Katz Z, Peeling R, Revill P.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw161. eCollection 2016 Sep. Erratum in: Open Forum Infect Dis. 2018 Jan 30;5(1):ofx181.

Supplemental Content

Loading ...
Support Center